




STATE MEDICAID P&T COMMITTEE MEETING

Thursday, January 16, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 114



MINUTES

Committee Members Present:

Kort Delost, R.Ph.

Ellie Brownstein, M.D.

Beth Johnson, R.Ph

Julia Ozbolt, M.D.

Roger Martenau, M.D.

Lisa Hunt, R.Ph.

Jameson Rice, Pharm.D.

Elizabeth Young, Pharm.D.

Bernadette Kiraly, M.D.

Committee Members Excused:

None

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D.

Richard Sorenson, RN

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Gary Oderda, Pharm.D, MPH

Bryan Larson, Pharm.D.

Other Individuals Present:

Scott Clegg, Lilly

D.R. McCale, Baxter

Lori Howarth, Bayer

Meeting conducted by: Kort Delost

1. **Review and Approval of December Minutes:** Minutes from December meeting were requested to be revised due to some errors found. Those minutes will be represented in the February meeting.
2. **Housekeeping:** Utah Medicaid is preparing a PDL for 2014 that should be released in January. The draft is posted on the Medicaid website.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the January meeting reviewed the criteria for insulin pens. For February she reported that the annual training will take place.
4. **Pediculicides and Scabicide agents:** Melissa Archer presented a review of Pediculicides and Scabicide agents. Peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

5. No Public comment

6. Committee discussion

- a. Kort Delost says that we should look at safety first, and determine if the agents are safe for children. He also said we should pay attention to the spectrum the products are intended, and what pests they treat.
 - b. Kort Delost clarifies that the OTC treatments are currently covered by Medicaid.
 - c. A question was asked about scabies treatment about the difference between permetherin, lindane, and crotamiton and the cure rates differences. Lindane should be used as a second line treatment.
 - d. Lisa Hunt states that she wants the committee to consider making a motion on three things. To include the class on the PDL, to determine that they are safe and effective enough to include on the PDL, and guidance on OTC coverage and pediatric coverage.
 - e. Kort Delost makes a motion saying that the pediculosides and scabisides agents are equally effective, but not equally safe for all populations. These agents should be considered for inclusion on the PDL. Roger Martenau seconded the motion. All in favor.
 - f. Ellie Brownstein makes a motion saying that based on utilization and pediatric indications, both strengths of permetherin be included on the PDL. Beth Johnson seconds the motion. All in favor.
- 7.** Next meeting is scheduled for February 20, 2014. Short acting opioid agents will be discussed.
- 8.** Ellie Brownstein makes a motion to adjourn. Beth Johnson seconds, all in favor.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov